StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Alnylam Pharmaceuticals's price to sales ratio was 4.4× on Nov 11, 2026, against 18.5× a year earlier. Over the last 5 years it ranged from 4.4× to 30.4×, with a median of 16.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.4×−11.9
2025Dec 31, 202516.3×+1.9
2024Dec 31, 202414.5×+0.5
2023Dec 29, 202313.9×−16.5
2022Dec 30, 202230.4×+3.4
2021Dec 31, 202127.0×−10.6
2020Dec 31, 202037.6×−38.2
2019Dec 31, 201975.8×−4.4
2018Dec 31, 201880.2×+76.1
2011Jul 29, 20114.1×+0.2
2010Dec 31, 20103.9×–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?